Xencor Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello and welcome to the Xencor ESMO 2026 webcast. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference call is being recorded today. If you have any objections, please disconnect at this time. I will now turn the call over to Charles Liles, Executive Director of Investor Relations and Corporate Communications.
Thank you and good morning. Yesterday, we issued a press release introducing the topics we plan to discuss on this webcast, including results from dose expansion cohorts of the phase I study of XmAb819 in advanced clear cell renal cell carcinoma. The press release is available at www.xencor.com. Providing comments on the call from Xencor are Bassil Dahiyat, President and Chief Executive Officer, John Desjarlais, Executive Vice President and Chief Scientific Officer, Dane Leone, Executive Vice President and Chief Strategy Officer, and Jeff Chou, Senior Vice President and Head of Clinical Development for Xencor's Oncology Programs. We are also joined by Dr. Sumanta Pal, Professor and Vice Chair of Academic Affairs, City of Hope Comprehensive Cancer Center, who will join us to review his presentation at the ESMO conference yesterday. After the prepared remarks and presentation, we will open up the call for management to address your questions.
Slides that we are using today should be visible here on the webcast and will be made available for download on the Events and Presentations page of our website around the time our remarks are concluded. Before we begin, I would like to remind you that during the course of this conference call, Xencor management may make forward-looking statements, including statements regarding the plans and objectives of management, future product offerings, and research and development programs, as well as future financial and operating results, future market conditions, future operations, the company's partnering efforts, and capital requirements. These forward-looking statements are not historical facts, but rather are based on current expectations and beliefs and are based on information currently available to us.
The outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from results anticipated by these forward-looking statements, including but not limited to those factors contained in the Risk Factors section of our most recently filed annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q. These statements speak only as of today, and we undertake no obligation to update them except as required by law. Now, I'll pass the call over to Bassil.
Thanks, Charles, and thank you for joining us today. We are absolutely delighted to share the data presented at ESMO yesterday on XmAb819 phase I expansion cohorts in clear cell renal cell carcinoma, and to give an update on our plans for the program. I think this data cements Xencor's position at the forefront in targeting solid tumors with T-cell engagers, an emerging modality that we think delivers precision immunotherapy against solid tumors by bringing the immune system to bear against just the right cells. Currently, there are two ongoing phase III programs, both with exciting data created by Xencor using our XmAb platform and 2+1 format for selective tumor targeting. ASP2138 at Astellas and xaluritamig at Amgen. We expect XmAb819 to be the third in pivotal studies when we start our planned trial in 2027.
We are not aware of any other TCE platform or company that has made this much progress against the enormous unmet need in solid tumor oncology. In addition to this, we are awaiting an update from our partner, J&J, for the combination of pasritamig with JNJ-9401 and XmAb CD28 bispecific. It is important to put this update into another context. We have spent the last three years focusing on excellence in clinical trial execution and strategy, trying to have Xencor realize the value from the incredibly promising XmAb molecules we create. You can see the accelerating pace of trials, and most critically, we expect the resulting multiple data readouts will continue through 2027, starting with initial phase I-B data from plamotamab in RA in two weeks at ACR. Then phase I data from XmAb412, our bispecific TL1A/IL23.
Then the primary endpoint of our global phase II-B study of XmAb942 in ulcerative colitis, plus further data updates from the ongoing studies of XmAb819. Now back to 819. The central problem in targeting RCC or any solid tumor is the near universal issue of expression of tumor-associated antigen targets in normal tissue, very often in vital organs. The best target distribution situation is where there is a high level in tumor cells, higher level in tumor cells than healthy cells, but these cases still have target in those healthy cells. Drugging solid tumor targets has been a compromise between high anti-tumor potency and hence impact, and high selectivity, which avoids toxicity. This 2x2 schematic illustrates the point. With highly active but toxic chemotherapy at the lower right, and at the top left, highly selective traditional monoclonals lacking potent killing mechanisms.
ADCs and first gen TCEs added very active cytotoxic functions to antibodies, chemo molecules, and T-cell recruitment, respectively. But they compromise selectivity, which you can see from ADC killing of low or even zero target tumor cells, and tox profiles reflecting their chemo ligand. For first gen TCEs, having tox challenges achieving and sustaining effective doses in solid tumor indications. With our 2+1 platform, we have been attempting to move TCEs up in selectivity without compromising anti-tumor activity, so we can broaden both therapeutic windows and use cases. Now I am going to turn it over to John Desjarlais, our longtime CSO and co-inventor of our XmAb platform, so he can describe how we did this to create 819 and the other 2+1s.
Thanks, Bassil. Since the XmAb 2+1 platform has been critical to ours and our partners' solid tumor T-cell engager strategy, I would like to review the general concept. First, the 2+1 format binds tumors like natural antibodies do. Specifically, we have bivalent targeting of the tumor antigen.
That provides us with a powerful engineering paradigm to create T-cell engagers with improved tumor versus normal selectivity. The way that works is we tune the affinity of the tumor targeting arm such that the antibody can retain high binding or avidity for high-density tumor cells expressing lots of the target while sparing normal cells that express lower levels of our target. That is a well-validated biophysical phenomenon due to the heightened ability of the second targeting arm to quickly find another target when there is lots of it around, like natural antibodies do. In contrast, when using a 1+1 bispecific, that single tumor targeting arm has to have sufficient affinity on its own to drive binding the tumor cells, meaning it is much harder to distinguish tumor from normal cells.
Because this is a well-understood biophysical phenomenon, we can develop QSP models to help us tune the tumor normal selectivity for a given target and its density ranges. Here on the top right plot, you can see a QSP-optimized XmAb 2+1 for a hypothetical target density of 30,000 and a normal density threefold lower. For this scenario, the model shows strong killing of the higher density tumor cells with significantly lower activity on normal cells. On the bottom right, if we take that same density range for a 1+1 bispecific, then you can see the model predicts very little discrimination between tumor and normal, which of course means it will have higher potential for safety issues. In fact, the only way to recover more selectivity with a 1+1 is to reduce its affinity, which then means we would struggle to have sufficient killing of tumor cells.
Now let us focus more specifically on XmAb819, Xencor's XmAb 2+1 that we developed for the treatment of kidney cancer. From the antibody diagram, you can see that it has two arms that bind ENPP3 and a single CD3 targeting arm. Of course, it was affinity/avidity tuned to optimize for tumor normal selectivity. The middle plot shows that nicely where we could see significantly more killing of a high-density tumor cell line versus one with lower ENPP3 expression. Finally, on the right plot, we are able to see strong anti-tumor activity of XmAb819 in our preclinical mouse tumor models. Notably, the same model is completely refractory to PD-1 blockade. Now, we initially developed XmAb819 for treatment of kidney cancer, specifically clear cell renal cell carcinoma, but we know the target is also expressed to some extent across a wide range of histologies.
As you can see from this large IHC data set we collected, ENPP3 is strongly and uniformly expressed in clear cell RCC. We also see a good proportion of papillary RCC patients expressing strong levels, and there is also a good number of microsatellite stable colorectal cancer patients and lung cancer patients that express significant levels. We have included some representative IHC images from some of these histologies on the right. Now that we have observed compelling activity in clear cell RCC, we recently opened cohorts for papillary RCC, colorectal cancer, and lung cancer. While we do not need to pre-screen for ENPP3 expression in clear cell, enrollment in these other cohorts is contingent on seeing strong expression by IHC. Xencor has always prioritized for the creation of modular antibody formats with high stability, developability, and robust manufacturing using straightforward purification protocols.
We believe this approach has borne out very well clinically, and we have been excited to see such compelling progress with many of our and our partners' clinical stage molecules. With such a strong backbone format for XmAb819, we have been happy to see a good pharmacokinetic profile in our patients. The plot here shows our fitted population PK profile for XmAb819 as we go through the priming and step-up phases of dosing up to 100, 200, and 400 microgram per kilogram target dose. The model fits a terminal half-life of approximately 8 days. That profile lends itself to dosing every 2 weeks or we believe 3-week dosing, particularly when we reach the target dose. The shaded areas of the plot show important regions for our QSP model of XmAb819 cytotoxicity with the EC50 to EC80 range shown in light gray, and the EC80 plus range shown in dark gray.
The model built with a combination of preclinical cytotoxicity and PK data predicts that at our highest IV dose of 400 microgram per kilogram, we are approaching the maximum activity of the drug with trough levels at 2-week dosing remaining above a predicted cytotoxicity of 80%. As I emphasized earlier, Xencor's platforms are built for robust stability, developability, and manufacturing. You can see from this summary table that we have a high titer cell bank for XmAb819 that scales well to 2,000 liter. Our drug substance and product are both stable for at least 60 months in liquid formulation. We are using commercially validated CDMOs for manufacturing in the U.S.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
